{"classes":[{"categories":[{"measurements":[{"comment":"Not enough events to calculate the data","groupId":"OG000","lowerLimit":"2.20","upperLimit":"NA","value":"4.90"},{"comment":"Not enough events to calculate the data","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not enough events to calculate the data","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not enough events to calculate the data","groupId":"OG003","lowerLimit":"2.30","upperLimit":"NA","value":"6.97"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed by Independent Radiology Committee.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG000","title":"Safety run-in Cohort 1"},{"description":"Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG001","title":"Safety run-in Cohort 2"},{"description":"Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG002","title":"Safety run-in Cohort 3"},{"description":"Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)\n\nAFM13: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion\n\nAB-101: NK cell therapy, intravenous infusion\n\nCyclophosphamide: Lymphodepleting chemotherapy, intravenous infusion\n\nFludarabine: Lymphodepleting chemotherapy, intravenous infusion\n\nInterleukin-2: Immune cytokine, subcutaneously","id":"OG003","title":"Safety run-in Cohort 4"}],"paramType":"MEDIAN","populationDescription":"All patients in the Safety Run In Set who had a response (CR or PR) assessed by the independent review committee.","reportingStatus":"POSTED","timeFrame":"Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)","title":"Duration of Response by Independent Radiology Committee","type":"SECONDARY","unitOfMeasure":"months"}